(
out of
64
reviews
)
Clinical Locations
Primary Location
Huntsman Cancer Institute - Cancer Research North
Clinic 2D/E, BMT/Hematology
2000 Circle of Hope
Salt Lake City
,
UT
84112
Patient Rating
Many patients praise Dr. Shami and his team for attentive, compassionate care, noting that he listens, explains things clearly, remembers personal details, and makes visits feel unhurried. Reviewers frequently mention the staff’s responsiveness and coordination, timely follow-up on test results, and instances where the team went above and beyond (including assistance with transplant-related matters). A small number of comments raised concerns about long wait times and one perceived degrading interaction, so not every experience was uniformly positive.
Generated via Patient Reviews
5.0
/5
( out of
64 reviews
)
The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
Board Certification and Academic Information
| Academic Departments |
Internal Medicine
-Professor |
|---|---|
| Academic Divisions |
Hematology & Hematologic Malignancies
|
Education history
| Undergraduate | Chemistry - American University of Beirut | B.S. |
|---|---|---|
| Professional Medical | Medicine - American University of Beirut | M.D. |
| Internship | Internal Medicine - Duke University Medical Center | Intern |
| Residency | Internal Medicine - Duke University Medical Center | Resident |
| Fellowship | Hematology/Oncology - Duke University Medical Center | Fellow |
Selected Publications
Journal Article
- McCarty RD, Trabert B, Millar MM, Kriebel D, Grieshober L, Barnard ME, Collin LJ, Gilreath JA, Shami PJ, Doherty J (2026). Associations Between Tattooing and Health Status: A Population-Based Cross-Sectional Study of Adults in Utah, 2020-2022. Public health reports (Washington, D.C., 333549261445868.
- Arellano ML, Thirman MJ, DiPersio JF, Heiblig M, Stein EM, Schuh AC, Zucenka A, De Botton S, Grove CS, Mannis GN, Papayannidis C, Perl AE, Issa GC, Aldoss I, Bajel A, Dickens DS, Kühn MWM, Mantzaris I, Raffoux E, Traer E, Amitai I, Döhner H, Greco C, Kovacsovics TJ, McMahon CM, Montesinos P, Pigneux A, Shami PJ, Stone RM, Wolach O, Harpel JG, Chudnovsky Y, Yu L, Bagley RG, Smith AR, Blachly J (2025). Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood,
- Wuliji N, Jones SMW, Gooley TA, Gerds AT, Medeiros BC, Shami PJ, Galvin JP, Adekola KUA, Luger SM, Baer MR, Rizzieri DA, Wildes T, Wang ES, Sekeres MA, Mukherjee S, Smith J, Garrison M, Kojouri K, Appelbaum JS, Percival MM, Sandmaier BM, Lee SJ, Appelbaum F, Rouce RH, Sorror M (2025). Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. Blood,
- Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, Mannis GN, Perl A, Dickens DS, McMahon CM, Traer E, Zwaan CM, Grove CS, Stone R, Shami PJ, Mantzaris I, Greenwood M, Shukla N, Cuglievan B, Kovacsovics T, Gu Y, Bagley RG, Madigan K, Chudnovsky Y, Nguyen HV, McNeer N, Stein E (2025). Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). Journal of clinical oncology, 43(1), 75-84.
- McCarty RD, Trabert B, Collin LJ, Millar MM, Kriebel D, Grieshober L, Barnard ME, Sawatzki J, Carter M, Yoder V, Gilreath JA, Grossman D, Hyngstrom J, Shami PJ, Doherty J (2025). Tattooing and risk of melanoma: a population-based case-control study in Utah. Journal of the National Cancer Institute, 117(12), 2495-2504.
- Li S, Li J, Faruque HA, Shami P, Knoechel B, Lohr J, Sborov D, Yang J, Kope'ek (2025). Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma. Advanced healthcare materials, 14(29), e02156.
- Krah NM, Hoeg R, Shami PJ, Elf SE, Lee LE, Pemmaraju N, Patel A (2025). Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base. Leukemia research reports, 24, 100541.
- McCarty RD, Trabert B, Kriebel D, Millar MM, Birmann BM, Grieshober L, Barnard ME, Collin LJ, Lawson-Michod KA, Gibson B, Sawatzki J, Carter M, Yoder V, Gilreath JA, Shami PJ, Doherty J (2024). Tattoos and Risk of Hematologic Cancer: A Population-Based Case-Control Study in Utah. Cancer medicine, 13(20), e70260.
- Li J, Gambles MT, Jones B, Williams JA, Camp NJ, Shami PJ, Yang J, Kope'ek (2024). Human serum albumin-based drug-free macromolecular therapeutics induce apoptosis in chronic lymphocytic leukemia patient cells by crosslinking of CD20 and/or CD38 receptors. Drug delivery and translational research, 14(8), 2203-2215.
- Shah B, Mattison RJ, Abboud R, Abdelmessieh P, Aldoss I, Burke PW, DeAngelo DJ, Dinner S, Fathi AT, Gauthier J, Haddadin M, Jain N, Jonas B, Kirby S, Liedtke M, Litzow M, Logan A, Long M, Luger S, Mangan JK, Massaro S, May W, Oluwole O, Park J, Przespolewski A, Rangaraju S, Saygin C, Schwartz M, Shami P, Tomlinson B, Webster J, Awotiwon A, Stehman (2024). Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22(8), 563-576.
- Gambles MT, Li S, Kendell I, Li J, Sborov D, Shami P, Yang J, Kope'ek (2024). Multiantigen T-Cell Hybridizers: A Two-Component T-Cell-Activating Therapy. ACS nano, 18(34), 23341-23353.
- Gambles MT, Sborov D, Shami P, Yang J, Kope'ek (2024). Obinutuzumab-Based Drug-Free Macromolecular Therapeutics Synergizes with Topoisomerase Inhibitors. Macromolecular bioscience, 24(3), e2300375.
- Sorror ML, Gooley TA, Storer BE, Gerds AT, Sekeres MA, Medeiros BC, Wang ES, Shami PJ, Adekola K, Luger S, Baer MR, Rizzieri DA, Wildes TM, Koprivnikar J, Smith J, Garrison M, Kojouri K, Schuler TA, Leisenring WM, Onstad LE, Becker PS, McCune JS, Lee SJ, Sandmaier BM, Appelbaum FR, Estey E (2023). An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML. Blood, 141(3), 295-308.
- Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Percival ME, Perl A, Przespolewski A, Rao D, Ravandi F, Shallis R, Shami PJ, Stein E, Stone RM, Sweet K, Thota S, Uy G, Vachhani P, Cassara CJ, Freedman-Cass DA, Stehman (2023). Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 21(5), 503-513.
- Shami P (2023). Development of JS-K, a First-in-Class Arylated Diazeniumdiolate, for the Treatment of Cancer. Critical reviews in oncogenesis, 28(1), 57-62.
- Pemmaraju N, Kantarjian H, Sweet K, Wang E, Senapati J, Wilson NR, Konopleva M, Frankel AE, Gupta V, Mesa R, Ulrickson M, Gorak E, Bhatia S, Budak-Alpdogan T, Mason J, Garcia-Romero MT, Lopez-Santiago N, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran J, Fathi AT, Hall AC, Jacoby MA, Lancet J, Mannis G, Stein AS, Mims A, Rizzieri D, Olin R, Perl A, Schiller G, Shami P, Stone RM, Strickland S, Wieduwilt MJ, Daver N, Ravandi F, Vasu S, Guzman M, Roboz GJ, Khoury J, Qazilbash M, Aung PP, Cuglievan B, Madanat Y, Kharfan-Dabaja MA, Pawlowska A, Taylor J, Tallman M, Dhakal P, Lane A (2023). North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood, 141(6), 567-578.
- Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, de Castro CM, Deeg HJ, DeZern AE, Dinner S, Foucar C, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Jonas BA, Keel S, Madanat Y, Maness LJ, Mangan J, McCurdy S, McMahon C, Patel B, Reddy VV, Sallman DA, Shallis R, Shami PJ, Thota S, Varshavsky-Yanovsky AN, Westervelt P, Hollinger E, Shead DA, Hochstetler (2022). NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. Journal of the National Comprehensive Cancer Network, 20(2), 106-117.
- Tommy Gambles M, Li J, Christopher Radford D, Sborov D, Shami P, Yang J, Kope'ek (2022). Simultaneous crosslinking of CD20 and CD38 receptors by drug-free macromolecular therapeutics enhances B cell apoptosis in vitro and in vivo. Journal of controlled release, 350, 584-599.
- Zhai Y, Dong S, Li H, Zhang Y, Shami P, Chen (2022). Antibody-mediated depletion of programmed death 1-positive (PD-1(+)) cells. Journal of controlled release, 349, 425-433.
- Watts J, Lin TL, Mims A, Patel P, Lee C, Shahidzadeh A, Shami P, Cull E, Cogle CR, Wang E, Uckun F (2022). Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA. Frontiers in oncology, 11, 806243.
- Sorror ML, Storer BE, Fathi AT, Brunner AM, Gerds AT, Sekeres MA, Mukherjee S, Medeiros BC, Wang ES, Vachhani P, Shami PJ, Peña E, Elsawy M, Adekola KUA, Luger S, Baer MR, Rizzieri D, Wildes T, Koprivnikar J, Smith J, Garrison M, Kojouri K, Leisenring WM, Onstad L, Nyland JE, Becker PS, McCune JS, Lee SJ, Sandmaier BM, Appelbaum F, Estey E (2021). Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. Blood,
- Sorror ML, Storer BE, Fathi AT, Brunner A, Gerds AT, Sekeres MA, Mukherjee S, Medeiros BC, Wang ES, Vachhani P, Shami PJ, Peña E, Elsawy M, Adekola K, Luger S, Baer MR, Rizzieri D, Wildes TM, Koprivnikar J, Smith J, Garrison M, Kojouri K, Leisenring W, Onstad L, Nyland JE, Becker PS, McCune JS, Lee SJ, Sandmaier BM, Appelbaum FR, Estey E (2021). Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. Blood, 138(5), 387-400.
- Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami P (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC cancer, 21(1), 510.
- Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran JM, Gojo I, Hall AC, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin MG, Mims A, Neff J, Nejati R, Olin R, Percival ME, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami PJ, Stone RM, Strickland SA, Sweet K, Vachhani P, Wieduwilt M, Gregory KM, Ogba N, Tallman M (2021). NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. Journal of the National Comprehensive Cancer Network, 19(1), 16-27.
- Uckun FM, Watts J, Mims AS, Patel P, Wang E, Shami PJ, Cull E, Lee C, Cogle CR, Lin T (2021). Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. Cancers, 13(21),
- Uckun FM, Lin TL, Mims AS, Patel P, Lee C, Shahidzadeh A, Shami PJ, Cull E, Cogle CR, Watts (2021). A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. Cancers, 13(16),
- Wang ES, Aplenc R, Chirnomas D, Dugan M, Fazal S, Iyer S, Lin TL, Nand S, Pierce KJ, Shami PJ, Vermette JJ, Abboud C (2020). Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. Leukemia & lymphoma, 61(8), 1965-1973.
- Patel AB, Pomicter AD, Yan D, Eiring AM, Antelope O, Schumacher JA, Kelley TW, Tantravahi SK, Kovacsovics TJ, Shami PJ, O'Hare T, Deininger M (2020). Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia, 34(11), 2981-2991.
- Willis C, Menon J, Unni S, Au T, Yoo M, Biskupiak J, Brixner D, Ndife B, Joseph G, Bonifacio G, Stein E, Tantravahi S, Shami PJ, Kovacsovics T, Stenehjem (2019). Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center. Leukemia research, 87, 106262.
- Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis G, Marcucci G, Martin MG, Mims A, O'Donnell MR, Olin R, Peker D, Perl A, Pollyea DA, Pratz K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory KM, OCN., Hammond L, Ogba (2019). Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 17(6), 721-749.
- Wang J, Li L, Yang J, Clair PM, Glenn MJ, Stephens DM, Radford DC, Kosak KM, Deininger MW, Shami PJ, Kope'ek (2019). Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine. Nanomedicine, 16, 217-225.
- Erba HP, Becker PS, Shami PJ, Grunwald MR, Flesher DL, Zhu M, Rasmussen E, Henary HA, Anderson AA, Wang E (2019). Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. Blood advances, 3(13), 1939-1949.
- Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, Brunner AM, Sekeres MA, Mukherjee S, Peña E, Elsawy M, Wardyn S, Whitten J, Moore R, Becker PS, McCune JS, Appelbaum FR, Estey E (2017). Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. JAMA oncology, 3(12), 1675-1682.
- Zhang R, Yang J, Zhou Y, Shami PJ, Kope'ek (2016). N-(2-Hydroxypropyl)methacrylamide Copolymer-Drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia. Macromolecular bioscience, 16(1), 121-8.
- Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi (2015). REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. British journal of haematology, 168(6), 796-805.
- Rudrapatna VK, Morley K, Boucher KM, Pierson AS, Shull CT, Kushner JP, Shami P (2015). Phase I trial of low-dose oral Clofarabine in myelodysplastic syndromes patients who have failed frontline therapy. Leukemia research, 39(8), 835-9.
- Kaur I, Kosak KM, Terrazas M, Herron JN, Kern SE, Boucher KM, Shami P (2015). Effect of a Pluronic(®) P123 formulation on the nitric oxide-generating drug JS-K. Pharmaceutical research, 32(4), 1395-406.
- Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C, National comprehensive cancer network (2015). Myelodysplastic syndromes, version 2.2015. Journal of the National Comprehensive Cancer Network, 13(3), 261-72.
- Chu TW, Zhang R, Yang J, Chao MP, Shami PJ, Kope'ek (2015). A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab. Theranostics, 5(8), 834-46.
- Stenehjem DD, Albright F, Kuo KL, Raimundo K, Bauer H, Shami PJ, Deininger MW, Chen L, Brixner D (2014). Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database. Journal of the National Comprehensive Cancer Network, 12(8), 1113-21.
- Chu TW, Kosak KM, Shami PJ, Kope'ek (2014). Drug-free macromolecular therapeutics induce apoptosis of patient chronic lymphocytic leukemia cells. Drug delivery and translational research, 4(5-6), 389-94.
- Zhuo R, Kosak KM, Sankar S, Wiles ET, Sun Y, Zhang J, Ayello J, Prestwich GD, Shami PJ, Cairo MS, Lessnick SL, Luo (2014). Targeting Glutathione S-transferase M4 in Ewing sarcoma. Frontiers in pediatrics, 2, 83.
- Kaur I, Terrazas M, Kosak KM, Kern SE, Boucher KM, Shami P (2013). Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles. The Journal of pharmacy and pharmacology, 65(9), 1329-36.
- Weidensteiner C, Reichardt W, Shami PJ, Saavedra JE, Keefer LK, Baumer B, Werres A, Jasinski R, Osterberg N, Weyerbrock (2013). Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI. Nitric oxide, 30, 17-25.
- Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, O'Donnell MR, Shami PJ, Stein BL, Stone RM, Thompson JE, Westervelt P, Wheeler B, Shead DA, Naganuma (2013). Myelodysplastic syndromes: clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 11(7), 838-74.
- O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Lancet J, Maness LJ, Marcucci G, Martin MG, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Wang ES, Gregory KM, Naganuma M, National Comprehensive Cancer Network (2013). Acute myeloid leukemia, version 2.2013. Journal of the National Comprehensive Cancer Network, 11(9), 1047-55.
- Narayanan S, Shami P (2012). Treatment of acute lymphoblastic leukemia in adults. Critical reviews in oncology/hematology, 81(1), 94-102.
- Nandurdikar RS, Maciag AE, Holland RJ, Cao Z, Shami PJ, Anderson LM, Keefer LK, Saavedra J (2012). Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs. Bioorganic & medicinal chemistry, 20(9), 3094-9.
- O'Brien S, Abboud CN, Akhtari M, Altman J, Berman E, DeAngelo DJ, Devine S, Fathi AT, Gotlib J, Jagasia M, Moore JO, Pinilla-Ibarz J, Radich JP, Reddy VV, Shah NP, Shami PJ, Smith BD, Snyder DS, Wetzler M, Yunus F, National Comprehensive Cancer Network (2012). Chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network, 10(1), 64-110.
- Shami P (2012). How to choose frontline therapy for chronic myelogenous leukemia: so many drugs, not so many patients. Journal of the National Comprehensive Cancer Network, 10(1), 112-8; quiz 119.
- O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, Lancet J, Maness LJ, Marcucci G, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, Naganuma M, Gregory K (2012). NCCN Clinical Practice Guidelines Acute myeloid leukemia. Journal of the National Comprehensive Cancer Network, 10(8), 984-1021.
- Slomowitz SJ, Shami P (2012). Management of extramedullary leukemia as a presentation of acute myeloid leukemia. Journal of the National Comprehensive Cancer Network, 10(9), 1165-9.
- Maciag AE, Holland RJ, Saavedra JE, Chakrapani H, Shami PJ, Keefer L (2012). Thiol Modification By Pharmacologically Active Agents of the Diazeniumdiolate Class. Forum on immunopathological diseases and therapeutics, 3(2), 91-95.
- Maciag AE, Nandurdikar RS, Hong SY, Chakrapani H, Diwan B, Morris NL, Shami PJ, Shiao YH, Anderson LM, Keefer LK, Saavedra J (2011). Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs. Journal of medicinal chemistry, 54(22), 7751-8.
- Maciag AE, Chakrapani H, Saavedra JE, Morris NL, Holland RJ, Kosak KM, Shami PJ, Anderson LM, Keefer L (2011). The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species. The Journal of pharmacology and experimental therapeutics, 336(2), 313-20.
- Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P, National Comprehensive Cancer Network (2011). NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network, 9(1), 30-56.
- O'Brien S, Berman E, Moore JO, Pinilla-Ibarz J, Radich JP, Shami PJ, Smith BD, Snyder DS, Sundar HM, Talpaz M, Wetzler (2011). NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network, 9 Suppl 2, S1-25.
- O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G, Maslak P, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, National Comprehensive Cancer Network (2011). Acute myeloid leukemia. Journal of the National Comprehensive Cancer Network, 9(3), 280-317.
- Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M, Petersdorf S, Shami PJ, Yeager AM, Eckert S, Abichandani R, Faderl (2010). Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. Journal of clinical oncology, 28(4), 549-55.
- Kantarjian HM, Erba HP, Claxton D, Arellano M, Craig M, Douer D, Gabrilove J, Lyons R, Kovascovics T, Maris M, Petersdorf S, Shami PJ, Yaeger A, Eckert S, Abichandani R, Faderl S, On behalf of the CLASSIC II Investigator (2010). Phase II Study of Clofarabine Induction and Consolidation Therapy In Previously Untreated Older Adults With Acute Myelogenous Leukemia for Whom Conventional Induction Chemotherapy is Unlikely to be of Benefit Due to Unfavorable Baseline Risk Factors. Journal of clinical oncology, 28, 549-555.
- Kiziltepe T, Anderson KC, Kutok JL, Jia L, Boucher KM, Saavedra JE, Keefer LK, Shami P (2010). JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo. The Journal of pharmacy and pharmacology, 62(1), 145-51.
- Kiziltepe T, Anderson KC, Kutock JL, Jia L, Boucher KM, Saavedra JE, Keefer LK, Shami P (2010). JS-K has Potent Anti-Angiogenic Activity In Vitro and Inhibits Tumor Angiogenesis in a Multiple Myeloma Model In Vivo. The Journal of pharmacy and pharmacology, 62, 145-151.
- Edes K, Cassidy P, Shami PJ, Moos P (2010). JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon cancer cells with knockdown of thioredoxin reductase 1. PloS one, 5(1), e8786.
- Liu J, Malavya S, Wang X, Saavedra JE, Keefer LK, Tokar E, Qu W, Waalkes MP, Shami P (2009). Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells. Genomics, 94(1), 32-8.
- Shami PJ, Maciag AE, Eddington JK, Udupi V, Kosak KM, Saavedra JE, Keefer L (2009). JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C). Leukemia research, 33(11), 1525-9.
- O'Brien S, Berman E, Borghaei H, Deangelo DJ, Devetten MP, Devine S, Erba HP, Gotlib J, Jagasia M, Moore JO, Mughal T, Pinilla-Ibarz J, Radich JP, Shah Md NP, Shami PJ, Smith BD, Snyder DS, Tallman MS, Talpaz M, Wetzler M, National Comprehensive Cancer Network (2009). NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network, 7(9), 984-1023.
- Saade M, Salamoun W, Tueni E, Shami P (1999). Who should be screened for hereditary breast cancer and what should be done with the information?. Le Journal medical libanais. The Lebanese medical journal, 47(5), 281-3.
- Shami PJ, Crews (1995). Megaloblastic cytopenia in an AIDS patient treated with trimethoprim-sulfamethoxazole. North Carolina medical journal, 56(12), 602-4.
- Ciaccia D, Quigley RL, Shami PJ, Grant J (1994). A case of retrograde jejunoduodenal intussusception caused by a feeding gastrostomy tube. Nutrition in clinical practice, 9(1), 18-21.
Review
- Shami PJ, Deininger (2012). Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia, 26(2), 214-24.
- Zeng J, Yang N, Li XM, Shami PJ, Zhan (2010). 4'-O-Methylglycosylation of Curcumin by Beauveria bassiana. Natural product communications, 5, 77-80.
Abstract
- Rudrapatna RK, Morley K, Kushner JP, Pierson AS, Shull CT, Shami P (2013). Phase I Trial of Low-Dose Oral Clofarabine in Myelodysplastic Syndromes Patients Who Have Failed Frontline Therapy.
- Rudrapatna R, Kosak KM, Terrazas M, Kennedy TP, Shami P (2010). Development of Dithiocarbamate/Metal Complexes in Pluronic® micelles for the Treatment of Malignancies. 5526.
- Kaur I, Kosak KM, Saavedra JE, Keefer LK, Kern Se, Shami P (2010). Cellular uptake and stability studies of the nitric oxide-generating pro-drug JS-K. 2651.
- Maciag AE, Chakrapani H, Holland RJ, Morris JL, Shami PJ, Saavedra JE, Anderson LM, Keefer L (2010). Diazeniumdiolate-based nitric oxide-releasing prodrugs kill lung adenocarcinoma in cells in culture and in vivo through alterations in cellular redox balance leading to mitochondrially-mediated apoptosis. 4547.
- Kosak KM, Saavedra JE, Keefer LK, Shami P (2009). A Pluronic® micelle formuation increases the stability of the novel anti-cancer nitric oxide prodrug JS-K. 643.
Dr Shami, is very knowledgeable, professional and has helped me greatly with my Leukemia treatment
I want to thank you dr. Shami. For helping me. And explain to me everything. So I can understand for the decision I make
Dr. Shami is amazing if you have to visit him you are going to feel like you are his only patient. He will never make you feel rushed or cut you off when asking questions. When I was first diagnosed with CML 6 years ago I did not know what to do or to expect and he walked me through each step taking the fear away every time. Cancer is scary and I do not wish this journey on anyone but Dr. Shami is the best!!!
Dr Shami, is so great he always is looking for ways to make sure I feel better, and is trying to find ways to cure my disease
Dr. Paul Shami is the best! He and his team are highly skilled and knowledgeable care-givers who have been part of my life for the past 6 years. I want to thank them for the incredible level of medical care they have given me. They work long hours and deal with people in such a fragile state. I can't thank them enough for all they have done to help me beat cancer!
Going into his exam room he was already up to speed on my condition and ready to give me answers. He spent as much time with my wife and I as we needed with out rushing us out.
For the disease I have I don't think there's a better doctor out there. Thank you, Dr. Shami.
Best Doctor ever seen! Very thorough! Very caring!
Dr. Shami answered our questions in detail. We really appreciate the time he gave us. We felt very comfortable during our visit and are very thankful to have him as Paul's doctor .
He cares a great deal about his patients and I feel very comfortable and confident at this point in my treatment
My amazing Dr Shami IS THE BEST DR in my world I'm very grateful for being his patient
See him
Dr Shami is the best !!!
Dr. Shami is kind, caring, professional, intelligent, and has great bedside manner. He really listens to you and answers questions in a way I understand. He is organized and prepared for each appointment, and thorough in the examination.
Dr Shami is a dedicated professional and always has your best interest as his goal in treating you.
One of the BEST Doctors I have ever worked with. He is kind, knowledgeable, and patient. He understands what we (his patients) are going through and is sensitive to our needs. He is very reasonable but also knows how much to give without compromising our health. I am SO grateful he is my doctor and is helping me through the fight of my life.
A great man
Dr. Paul Shami is the epitome of a professional and caring doctor. I have seen him for 12 years and he has always listened to my needs and communicated with me to alleviate my concerns and provide guidance during all of my health challenges. Now he is collaborating with another HCI doctor to ensure my surgery is safe and effective. Thank you, Dr. Shami, for all you have done for me. [NAME REMOVED]
A wonderful doctor. I would recommend him to anyone who is in need of a hematologist.
Dr. Paul Shami, Lexy, and Jordan listen to every request and include me in their decisions. Their immediate response to my messages on the portal is so very much appreciated.
Dr. Shami is through and explains things so I can understand. He inspires confidence with his quiet manner.
Was very patient and detailed things in a way I could understand. Took his time and seemed very interested in helping me through my process.
All appointments with Dr. Shami provide me with more information about my health. He cares deeply for his patients. Every question is answered right at my appointment so I leave with copious notes on how to take care of myself and what the needed next steps might be.He is so respected by everyone on his staff; that is easy to see.
He is incredibly kind, thorough and knowledgeable.
Wonderful team, I am blessed to have them taking care of my needs
Dr. Shami is wonderful. He has treated me very well over the past 3 years.
Dr Shami spent a great deal of time examining me, explaining the lab results, discussing various treatments and discussing long term outcomes.
I believe he's quite concerned about my care. Provide me with good information.
Met for the first time but he's great.He really care about your health,explain everything to me very clearly.
He treated me in a professional and respectful manner.
Dr Shami is awesome. He is my favorite
Cares about the individual!
Amazing Doctor¿ extremely thorough¿ I am very thankful to be seeking his care¿
Dr Shami is very thorough and well prepared. I was extremely happy with our meeting.
Excellent Doctor. Thorough, thoughtful and highly qualified.
Dr Shami is the best and most knowledgeable.
He was very patient and thorough.
He's the BEST DR ever. I'm very grateful for being his patient
He is the very best hematologist/oncologist hands down. I trust him with my life'very literally.
A1 Doctor and Human Being
Dr. Shami is extremely knowledgeable and extremely competent, and he is working to help me.
Dr Shami is very thorough, caring and knowledgeable. He explained everything so clearly and answered all my questions.
Dr. Shami is absolutely the best caregiver of all my doctors. He listens to our concerns and questions. He explains so his information is easy to understand. Dr. Shami cares about me as a person as well as a patient and remembers so much about my interests. He is the reason we drive 300 miles to see him whenever he says to come to Huntsman. Thank you, Dr. Shami, for saving my life eleven years ago and continuing to monitor my health.
Very professional, thorough, extremely caring. Personal, trust him to do what is best for me in a timely manner.
I have had an excellent experience with Dr. Shami. I feel very secure with his care.
Dr Sami is the best
Dr. Shami is not only my doctor, but I also view him as a friend. I feel his concern for me as a person...not just as a patient. He explains everything in easy to understand words. I have a great deal of trust in his abilities to provide any treatment I may need.
Dr. Shami is extremely thorough. He takes time with his patients, listens and explains things in ways that make sense.
Talking with Dr. Shami was easy and he explained things in a way that we could understand. He is a very caring person and we felt very comfortable with him.
The only Dr. I trust
Dr Shami is one of the finest doctors Ive ever worked with. He is so kind and caring in his approach. He is incredibly knowledgeable and has a great intuitive sense for his patients. I flew from Hawaii to continue working with him because of the trust I have in his advise and the wonderful way I am always treated.
Very Good experience. He was very Thorough in every thing. His explainations concerning my individual Situation and options for treatment Were very well explained.
Dr. Shami is the best oncologist out there he not only treats your cancer, he listens to your questions, concerns and frustrations. He gets to know you as a person as well as your family.
Excellent Dr. that listens carefully and explains issues.
I was impressed with the amount of individual time he took with me. He answered all my questions and concerns in a manner I understood.
Dr. shamis a good doctor treats me very well its very concerned in my condition keeps me very well informed if I have questions she answers very satisfied very satisfied with my doctor
We had a very good, comfortable, and enlightening experience with Dr. Paul Shami. He proved himself to be painstaking thorough on background information. We felt he really cared. We didnt feel processed.
Dr Shami is the best and we trust his knowledge and counsel.
Thank you Dr. Shami you are the best!!!
He is excellent and I am fortunate to have him as my physician..
I have been seeing Dr. Paul Sham since 2003.He cares about his patients. Explains Options and help.I could not have a better physician to manage my CLL
Best of the best in my book. Very thorough and extremely knowledgeable about MDS.
I wish I get my tests results
Dr. Shami is simply the best. He is kind, personable,patient and caring. We are so fortunate to be under his care.
Dr. Shami was very thorough with every aspect concerning my affliction, I felt that It was of utmost importance to him that I was educated and fully understood.
Dr Shami is the best. He is ready to listen and then answer my questions, so I understand. He always makes me a part of my treatment plan. I always recommend him to others who need his specialty, but insurance companies are in charge of who patients can see so until that changes we patients can only do so much.
We waited 2 hours for him to come in the exam room. He only came in because we saw his nurse as we were leaving and she said she would run and get him. We made a one way two hour drive only to wait two hours unnecessarily and after our appt time. I understand being late to the appts because of the nature of appts that happen at huntsman, but that was not reasonable. The doctor appeared annoyed because we had asked him if we could come every 6 months instead of every 3. I didn't see the reason for that nor was it clearly explained to me. Instead he said that I need to take my cancer more seriously. And basically talked to me like I was non-compliant even though I've never missed an appt medication, etc. His lecture came across as degrading whether he intended that or not. I have him to thank though as it never occurred to me I could transfer care to a closer hospital clinic until I left huntsman feeling degraded. So I will be transferring care and will not be recommending this doctor to other patients.
Dr.Shami is outstanding. Very thorough and kind.
Dr Shami is one of the all time best medical professionals I've dealt with. I'm so grateful for his expertise, intuitive skills and kindness he always shows to me.
We love Dr Shami. The man is flawless from the Carvers perspective.
Dr. Shami is simply amazing. We really can't say more. We sing his praises to everyone who will listen.
I was very nervous and my husband could not be with me so I was very emotional which I did not expect. Everyone was so kind thank you
Dr Shami is the best and very thorough
Excellent care
Very positive experience with Dr. Paul Shami - a very wise and knowledgeable individual
Dr. Shami and his staff are attentive, professional, and concerned. They listen and make me a part of my care.
Our visit was NOT virtual. The attention we got in the pharmacy, reception, blood-drawing, and with Dr Shami's staff was first rate. It could not have been better. Kind, considerate, and expert in all aspects!
Very good
I am very fortunate to be in Dr. Shami's care. Very knowledgeable and most personable,
We feel blessed being under Dr. Shami's care and will be back soon to be in person.
Over all it's all good
Dr Shami is a gifted medical professional and such a kind and compassionate man. His level and style of care feel like it lends itself to my confidence in healing in a timely manner.
Excellent, as always!
Dr. Shami was excellent! This was one of the most thorough examinations that I have ever had! HCI is very fortunate to have him on Its staff. I would not hesitate to be seen by him again for examination or treatment.
Very good
We love Dr. Shami and Andi. The nursing staff is outstanding as well.
As always, Dr Shami is one of the most outstanding medical professionals I have ever worked with. He is an excellent listener, explains options very clearly, is kind and empathetic as well as always respectful and encouraging.
I have no complaints regarding Dr. Shami. he is my care provider and I can say there is none better. He listens to be and allows me to express what I think and together we plan our next course. he is the best doctor I have ever had
Dr. Shami has a very difficult job, he does it very good.
Dr Shami is literally one of the finest medical professionals I have ever encountered. We have run CME Conferences for many years and he is absolutely one of the most gifted and humble doctors I've ever been acquainted with. His level of compassion and concern for my wellbeing seems to have an overarching healing capacity, simply because of his gifted and caring demeanor.
Dr Shami makes my husband and me feel like we are his only patients. He is kind, caring and extremely professional. I feel like I literally owe my life to him and Dr. Patel.
Dr. Shami is always asks for my input, listens to my questions, and includes me in decisions regarding my treatment plan. HIs explanations are easy to understand and he takes time to make sure we are on the same page.
We cannot say enough about Dr. Shami, his associates, staff and the pharmacists. Very Good does not go far enough to describe our experience. We would not change a thing.
Dr Shami was very personable and quite thorough in getting background on me. My wife and I were very pleased with the time and methodology during the visit.
good
Dr Shami is such a fine man. Very calm, reassuring and knowledgeable. I'm so grateful for his gentle service in my behalf.
great doctor Dr Shami. and great staff.
very understanding (good)
very good
Such a Fabulous Facility and Staff. I'm so fortunate to be able to be under Dr. Shami's care. My husband and I both highly recommend HCI to our friends and family.
Dr Shami is a most remarkable Medical Professional. I am truly honored to work with him. I have seen miracles happen with my health and i contribute some of this to the level of care and healing compassionate service I have received from Dr Shami and his team.
Dr Shami does an outstanding listening,explaining, and responding
Dr. Shami is a superb Doctor and a great and caring man.
Dr. Shami is the best.
Dr. Shami was very nice and listened and explained everything and then took time to answer all my questions. I felt very comfortable and at ease with Dr.Shami.
very good to work with arranged for treatments in Rock Springs, Wy
They went out of their way to help me.
Dr.Shami I cared about his patients.
Dr Shami is amazing. He has an extraordinary ability to communicate complex problems in understandable ways. He takes time to listen to my concerns and then works to find acceptable solutions. I could not be happier with the care he is providing. I sing his praises to anyone who'll listen.
I feel completely blessed to be here and I have every confidence that I am going to get well. I didn't have that same confidence in Las Vegas, where I am from. I actually had a doctor in Las Vegas come into my hospital room and told me that if I wanted to survive this Leukemia that I needed to get out of Las Vegas and get to either the Mayo Clinic in Arizona or the The Huntsman Cancer Center in Salt Lake City. Of course I opted for Huntsman and I am so glad that I did,
never feel rushed. Dr Shami and team are always willing to answer any questions. it is an amazing experience during a difficult time.
Dr. Shami and his team always make me feel as though I'm their only patient. His explanations regarding my disease and possible outcomes are clear and easy to understand. He provides the information in a kind, empathetic manner. He is superb.
very good at giving us great options while also outlining the risks.
Dr Shami and his associates are amazing